Custom Search
FDA Information
In 2004, Aventis announced that the U.S. Food and Drug Administration (FDA) has approved Nasacort HFA Nasal Aerosol® (triamcinolone acetonide) for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and children age 6 and older.
Nasacort HFA Nasal Aerosol® is the first intranasal corticosteroid dry-aerosol formulation approved in the U.S. that contains hydrofluoroalkane (HFA), rather than chlorofluorocarbons (CFCs).
Why is this medication prescribed?
Dosage and using this medicine
What special precautions should I follow?
What should I do if I forget a dose?
What side effects can this medication cause?